Pharmaplan AG
Pharmaplan AG, headquartered in France, is a leading player in the pharmaceutical and biotechnology industry, specialising in the design and construction of facilities for the production of medicines. Founded in 1971, the company has established a strong presence across Europe and beyond, delivering innovative solutions tailored to the unique needs of its clients. With a focus on project management, engineering, and consulting services, Pharmaplan AG stands out for its commitment to quality and compliance with stringent regulatory standards. The company’s expertise in creating state-of-the-art production environments has earned it a reputation for excellence, making it a trusted partner for major pharmaceutical firms. Pharmaplan AG's notable achievements include successful collaborations on high-profile projects, reinforcing its position as a key player in the global market. Through its dedication to innovation and customer satisfaction, Pharmaplan AG continues to shape the future of pharmaceutical manufacturing.
DitchCarbon Score
How does Pharmaplan AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pharmaplan AG's score of 6 is lower than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaplan AG's reported carbon emissions
Pharmaplan AG, headquartered in France, currently does not have available data on its carbon emissions, as no specific emissions figures have been provided. Additionally, there are no documented reduction targets or climate pledges outlined in their initiatives. This absence of data suggests that Pharmaplan AG may still be in the early stages of formalising its climate commitments or reporting on its carbon footprint. As the pharmaceutical industry increasingly prioritises sustainability, it is essential for companies like Pharmaplan AG to establish clear emissions reduction strategies and targets to align with global climate goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pharmaplan AG is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
